Skip to main content
LD

LEX Diagnostics

LEX Diagnostics develops a multiplex PCR system for point-of-care settings, enabling the rapid detection of respiratory infections such as Flu A, Flu B, and COVID-19 with positive results in as little as five minutes. This technology provides timely diagnostics during a single patient visit, improving clinical decision-making and reducing the strain on healthcare resources.

Melbourne, United KingdomFounded 2020405K+ followers
Updated 4 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current diagnostic methods for respiratory infections often involve lab processing, resulting in delayed results and hindering timely clinical decisions at the point of care. Traditional PCR testing can be slow, requiring batching and specialized equipment, which increases turnaround time and costs. This can lead to delayed treatment and increased risk of transmission.

Solution

LEX Diagnostics offers the LEX VELO system, an ultra-fast, point-of-care molecular diagnostics platform designed to deliver lab-quality PCR results directly from a swab sample in under 10 minutes, with positive results reported in as little as 6 minutes. The system utilizes proprietary ultra-fast thermal cycling technology to accelerate PCR analysis. The LEX system features a fully automated swab-to-result workflow that requires no liquid sample handling, reducing hands-on time and minimizing the risk of infection. Its compact footprint is designed for use in CLIA-waived settings such as physician’s offices, pharmacies, and urgent care facilities, enabling time and cost-efficient results during a single appointment.

Target Audience

The primary target audience includes healthcare professionals in primary care, urgent care, pharmacies, and decentralized acute settings who require rapid and accurate diagnostic results for respiratory infections at the point of care.

Features

  • Ultra-fast thermal cycling technology for rapid PCR analysis
  • Multiplex testing for the detection and differentiation of Flu A, Flu B, and COVID-19
  • Fully automated swab-to-result workflow with no liquid sample handling
  • Positive results reported in as little as 6 minutes; negative results in under 10 minutes
  • Compact system designed for point-of-care settings
  • Designed for use in CLIA-waived settings
  • Plans to expand respiratory test menu to include RSV and Strep A tests
This profile is AI-generated and may contain inaccuracies.